Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia

Reference:

Blunt, M. D. and Ward, S. G., 2012. Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia. Current Opinion in Pharmacology, 12 (4), pp. 444-451.

Official URL:

http://dx.doi.org/10.1016/j.coph.2012.02.015

Abstract

PI3K is critical for the normal function of the immune system, however dysregulated PI3K mediated signaling has been linked to the development of many immune mediated pathologies. This review describes current progress in the development of isoform-specific PI3K inhibitors that hold promise for the treatment of hematopoietic malignancies as well as for inflammatory and autoimmune diseases. A SH2-domain containing inositol-5-phosphatase (SHIP) is a regulator of PI3K signaling, and is also discussed as a potential drug target for immunomodulation and the treatment of leukemia. Recent progress has been made in the development of small molecule compounds that potently and selectively modulate SHIP activity and hence provide a novel mechanism to alter PI3K mediated signaling.

Details

Item Type	Articles
Creators	Blunt, M. D.and Ward, S. G.
DOI	10.1016/j.coph.2012.02.015
Departments	Faculty of Science > Pharmacy & Pharmacology
Publisher Statement	Ward_COP_2012.pdf: NOTICE: this is the author’s version of a work that was accepted for publication in Current Opinion in Pharmacology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Current Opinion in Pharmacology, 2012, vol 12, issue 4, DOI 10.1016/j.coph.2012.02.015; Ward_COP_2012.doc: NOTICE: this is the author’s version of a work that was accepted for publication in Current Opinion in Pharmacology. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Current Opinion in Pharmacology, 2012, DOI 10.1016/j.coph.2012.02.015
Refereed	Yes
Status	Published
ID Code	29619